Weight Loss Drugs Curb Alcohol Cravings?

Weight loss medications, including semaglutide (Wegovy) and tirzepatide (Mounjaro), may offer a new avenue for managing alcohol use disorder. A recent analysis of over 40,000 individuals indicated that these GLP-1 drugs are linked to a substantial reduction in alcohol-related hospital admissions.

The study found that GLP-1 medications slashed the risk of alcohol-related hospital admissions by 26% when compared to other diabetes treatments. For individuals using these drugs specifically for weight loss, the risk was 32% lower than with alternative obesity medications.

Further analysis revealed even more significant reductions. Among type 2 diabetics with alcohol problems, GLP-1s lowered admission risk by 63%, and for obese individuals with alcohol issues, the risk dropped by 65%. These findings, published in BMJ Open, suggest a potential role for GLP-1s in treating alcohol use disorder, though researchers emphasize that further investigation is necessary.

Experts acknowledge the growing body of evidence supporting GLP-1s' potential to mitigate alcohol-related harm. However, they also note that this is a US-based observational study. The high cost of newer GLP-1s means that users may differ from non-users, potentially introducing biases that are not fully accounted for.